Who is eligible for clinical trial NCT03737643?

Participants must meet protocol criteria for Advanced Ovarian Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT03737643 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-03

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (NCT03737643)

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Who can join: Review the eligibility criteria below.

Location: Research Site — Foothill Ranch, California

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (214 Sites)

Showing the first 25 of 214 sites.

Research Site — Foothill Ranch, California
Research Site — Los Angeles, California
Research Site — Orange, California
Research Site — San Francisco, California
Research Site — Tampa, Florida
Research Site — Augusta, Georgia
Research Site — Hinsdale, Illinois
Research Site — Indianapolis, Indiana
Research Site — Towson, Maryland
Research Site — Detroit, Michigan
Research Site — Springfield, Missouri
Research Site — Middletown, New Jersey
Research Site — Montvale, New Jersey
Research Site — Albany, New York
Research Site — New York, New York
Research Site — Uniondale, New York
Research Site — Durham, North Carolina
Research Site — Cleveland, Ohio
Research Site — Dayton, Ohio
Research Site — Hilliard, Ohio
Research Site — Tulsa, Oklahoma
Research Site — Lancaster, Pennsylvania
Research Site — Philadelphia, Pennsylvania
Research Site — Philadelphia, Pennsylvania
Research Site — Pittsburgh, Pennsylvania

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Ovarian Cancer

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer — Seattle, Washington
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer — Oklahoma City, Oklahoma

Explore by condition: All Advanced Ovarian Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗